Abstract Number: 715 • 2019 ACR/ARP Annual Meeting
Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review
Background/Purpose: Systemic sclerosis (SSc) is a chronic, auto-immune disease characterised by a widespread vasculopathy. There is a high need to obtain validated outcome measures for…Abstract Number: 716 • 2019 ACR/ARP Annual Meeting
Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients
Background/Purpose: The purpose of this pilot study is to identify, in a cohort of Systemic Sclerosis (SSc) patients, a “very early” nailfold videocapillaroscopy (NVC) pattern…Abstract Number: 717 • 2019 ACR/ARP Annual Meeting
Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities
Background/Purpose: Background: Systemic sclerosis (SSc) is a rare multisystemic autoimmune disease characterized by microvascular damage and progressive fibrosis of skin and internal organs. Global oral health…Abstract Number: 718 • 2019 ACR/ARP Annual Meeting
Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions
Background/Purpose: Pre-capillary pulmonary hypertension (PH) is a feared complication in patients with systemic sclerosis (SSc) and is associated with high mortality despite new treatment options.…Abstract Number: 719 • 2019 ACR/ARP Annual Meeting
Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth
Background/Purpose: The gastrointestinal tract (GIT) is commonly involved in SSc with up to 98% of patients reporting GIT manifestations. Small intestinal bacterial overgrowth (SIBO) is…Abstract Number: 720 • 2019 ACR/ARP Annual Meeting
Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: We report the baseline characteristics of a large cohort of diffuse cutaneous systemic sclerosis (dcSSc) patients enrolled in a Phase 3 trial of lenabasum,…Abstract Number: 721 • 2019 ACR/ARP Annual Meeting
Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease
Background/Purpose: Lung involvement is the leading cause of death in systemic sclerosis (SSc) (1). Pulmonary function tests (PFTs) and chest high-resolution CT scan (HRCT) are…Abstract Number: 722 • 2019 ACR/ARP Annual Meeting
The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major complication in systemic sclerosis (SSc) and is characterized by abnormalities in vascular pathways. In murine models of…Abstract Number: 723 • 2019 ACR/ARP Annual Meeting
Diagnosis of Systemic Sclerosis: How and When
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disease regarding its clinical expression, evolution and forms of presentation. In spite of the lack of a disease…Abstract Number: L15 • 2018 ACR/ARHP Annual Meeting
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Background/Purpose: The diagnostic accuracy of PET/CT against temporal artery biopsy (TAB) in patients suspected of having GCA has not been well studied. PET/CT has traditionally…Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…Abstract Number: L19 • 2018 ACR/ARHP Annual Meeting
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition associated with pain and fatigue, especially during physical activity. Treatments designed to modulate central pain pathways to…Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…